SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001193125-19-297713
Filing Date
2019-11-21
Accepted
2019-11-21 17:28:04
Documents
4
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G d837853dsc13g.htm SC 13G 64055
2 EX-99.1 d837853dex991.htm EX-99.1 18583
3 EX-99.2 d837853dex992.htm EX-99.2 4219
4 EX-99.3 d837853dex993.htm EX-99.3 5367
  Complete submission text file 0001193125-19-297713.txt   93776
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 2 WEST LIBERTY BLVD #100 MALVERN PA 19355
Business Address 2 WEST LIBERTY BLVD #100 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Subject) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91201 | Film No.: 191238148
SIC: 2834 Pharmaceutical Preparations